Abstract
Currently, the surgical management of pancreas cancer is recognized around the world as inadequate. Longterm survival is rare even though there is a potentially curative R0 resection. There is a strong rationale for the use of chemotherapy in the operating room to reduce local-regional and hepatic sites of recurrent/progressive disease. Gemcitabine monotherapy administered by an intraperitoneal route in the operating room with hyperthermia and then for long-term treatment postoperatively has a strong pharmacologic basis. The exposure of peritoneal surfaces to intraperitoneal gemcitabine is approximately 500 times the exposure that occurs within the plasma. By analogy to another lethal disease, ovarian cancer, intraperitoneal gemcitabine chemotherapy used following potentially curative resection is supported. Data that shows a superiority of multiagent chemotherapy to gemcitabine monotherapy has not been reported. A standardized treatment with intraoperative chemotherapy monitoring of gemcitabine would greatly facilitate further improvements in pancreas cancer treatment and lead the way to an evolution of more successful treatment strategies of this dread disease. The aim of this review is to present the recent available medical information and patents applicable to patients with resected pancreatic cancer.
Keywords: Chemotherapy, mortality, morbidity, randomized trials, pancreatic cancer, chemoradiation, European Organization for Research and Treatment of Cancer (EORTC)
Recent Patents on Anti-Cancer Drug Discovery
Title: Rationale for an Intraperitoneal Gemcitabine Chemotherapy Treatment for Patients with Resected Pancreatic Cancer
Volume: 4 Issue: 2
Author(s): Anil Kamath, Dal Yoo, Oswald A. Stuart, Lana Bijelic and Paul H. Sugarbaker
Affiliation:
Keywords: Chemotherapy, mortality, morbidity, randomized trials, pancreatic cancer, chemoradiation, European Organization for Research and Treatment of Cancer (EORTC)
Abstract: Currently, the surgical management of pancreas cancer is recognized around the world as inadequate. Longterm survival is rare even though there is a potentially curative R0 resection. There is a strong rationale for the use of chemotherapy in the operating room to reduce local-regional and hepatic sites of recurrent/progressive disease. Gemcitabine monotherapy administered by an intraperitoneal route in the operating room with hyperthermia and then for long-term treatment postoperatively has a strong pharmacologic basis. The exposure of peritoneal surfaces to intraperitoneal gemcitabine is approximately 500 times the exposure that occurs within the plasma. By analogy to another lethal disease, ovarian cancer, intraperitoneal gemcitabine chemotherapy used following potentially curative resection is supported. Data that shows a superiority of multiagent chemotherapy to gemcitabine monotherapy has not been reported. A standardized treatment with intraoperative chemotherapy monitoring of gemcitabine would greatly facilitate further improvements in pancreas cancer treatment and lead the way to an evolution of more successful treatment strategies of this dread disease. The aim of this review is to present the recent available medical information and patents applicable to patients with resected pancreatic cancer.
Export Options
About this article
Cite this article as:
Kamath Anil, Yoo Dal, Stuart A. Oswald, Bijelic Lana and Sugarbaker H. Paul, Rationale for an Intraperitoneal Gemcitabine Chemotherapy Treatment for Patients with Resected Pancreatic Cancer, Recent Patents on Anti-Cancer Drug Discovery 2009; 4 (2) . https://dx.doi.org/10.2174/157489209788452876
DOI https://dx.doi.org/10.2174/157489209788452876 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
System Level Meta-analysis of Microarray Datasets for Elucidation of Diabetes Mellitus Pathobiology
Current Genomics Lectins in Human Cancer: Both a Devil and an Angel?
Current Protein & Peptide Science Lipid Mediator Profiling in Pulmonary Disease
Current Pharmaceutical Biotechnology Advances in Peptide Pharmaceuticals
Current Pharmaceutical Biotechnology Lynch Syndrome: Awareness among Medical Students at a United States Medical School
Current Women`s Health Reviews The Male Peripubertal Phase as a Developmental Window for Reproductive Toxicology Studies
Current Pharmaceutical Design Synthesis of 1,2,3-triazole Compounds by Click Chemistry in Aqueous Medium and Evaluation of Bactericidal and Antitumoral Properties
Current Bioactive Compounds Exploring the Possible Prognostic Role of B-Lymphocyte Stimulator (BLyS) in a Large Series of Patients with Neuroendocrine Tumors
Endocrine, Metabolic & Immune Disorders - Drug Targets Cardiovascular Effects of Current and Future Anti-Obesity Drugs
Current Vascular Pharmacology A Chemical Genetics Approach for Specific Differentiation of Stem Cells to Somatic Cells: A New Promising Therapeutical Approach
Combinatorial Chemistry & High Throughput Screening “Dipeptoids”: From the Chemical Structure of the Endogenous Peptide to the Design of Peptidomimetics
Mini-Reviews in Medicinal Chemistry Chemoprevention of Lung Pathologies by Dietary n-3 Polyunsaturated Fatty Acids
Current Medicinal Chemistry Critical Role of the Endocannabinoid System in the Regulation of Food Intake and Energy Metabolism, with Phylogenetic, Developmental, and Pathophysiological Implications
Endocrine, Metabolic & Immune Disorders - Drug Targets The Small Heat Shock Protein HspB8: Role in Nervous System Physiology and Pathology
CNS & Neurological Disorders - Drug Targets Analysis of Carcinogenic Polycyclic Aromatic Hydrocarbons (PAHS): An Overview of Modern Electroanalytical Techniques and their Applications
Current Drug Delivery Evaluation of Drug Transporter Interactions in Drug Discovery and Development
Combinatorial Chemistry & High Throughput Screening Disposition of Flavonoids Impacts their Efficacy and Safety
Current Drug Metabolism Editorial [Hot Topic: Cancer and Stem Cells (Guest Editor: Eiichi Tahara)]
Current Cancer Therapy Reviews Emerging Therapeutic Potential of Whey Proteins and Peptides
Current Pharmaceutical Design Inflammation and Chronic Oxidative Stress in Radiation-Induced Late Normal Tissue Injury: Therapeutic Implications
Current Medicinal Chemistry